Abby Martens, APRN
Adult Health · Springdale, ARNPI 1821682238
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Verity Pharmaceuticals Inc. accounts for 67.9% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2023 at $5,411 and has fallen 87.9% since, to $657 in 2025. Among adult health clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $47.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verity Pharmaceuticals Inc.$5K
- Regeneron Healthcare Solutions, Inc.$280
- Novartis$273
- Johnson & Johnson$246
- Daiichi Sankyo Inc.$164
- Incyte Corporation$113
- plus $1K from 33 others
What the payments were for
- Food & beverage$7,18199%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Verity Pharmaceuticals Inc. | 3 | $4,941 |
| Regeneron Healthcare Solutions, Inc. | 20 | $280 |
| Novartis | 18 | $273 |
| Johnson & Johnson | 14 | $246 |
| Daiichi Sankyo Inc. | 10 | $164 |
| Incyte Corporation | 2 | $113 |
| Merck | 7 | $108 |
| Jazz Pharmaceuticals Inc. | 7 | $94 |
| Iovance Biotherapeutics, Inc. | 6 | $90 |
| Eisai Inc. | 6 | $83 |
| Sanofi | 5 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $74 |
| Tersera Therapeutics LLC | 5 | $63 |
| Ipsen Biopharmaceuticals, Inc | 4 | $61 |
| Amgen | 2 | $48 |
| AbbVie | 3 | $45 |
| Lilly USA, LLC | 2 | $42 |
| Dendreon Pharmaceuticals LLC | 3 | $41 |
| Taiho Oncology, Inc. | 2 | $38 |
| AstraZeneca | 3 | $38 |
| Geron Corporation | 2 | $36 |
| Bristol Myers Squibb | 2 | $35 |
| AVEO Pharmaceuticals, Inc. | 2 | $29 |
| Exelixis Inc. | 2 | $27 |
| Seagen Inc. | 2 | $26 |
| Beigene USA, Inc. | 2 | $26 |
| Bayer | 2 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| EMD Serono, Inc. | 1 | $17 |
| Sobi, Inc | 1 | $15 |
| Deciphera Pharmaceuticals Inc. | 1 | $14 |
| Morphosys, US Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
| Acceleron Pharma, Inc. | 1 | $12 |
| Blueprint Medicines Corporation | 1 | $12 |
| Secura Bio, Inc. | 1 | $11 |
| G1 Therapeutics, Inc. | 1 | $11 |
| Genentech USA, Inc. | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELSTAR$4,925
How this compares
$7,281 in reported general payments places this provider in the 90th percentile of 154 adult health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 33 | $24,112 |
| BelbucaBuprenorphine Hcl | 22 | $15,353 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 184 | $4,321 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $3,668 |
| Pregabalin | 168 | $3,268 |
| Olanzapine | 81 | $2,233 |
| Buprenorphine | 11 | $2,157 |
| Buprenorphine Hcl | 38 | $1,752 |
| Bupropion XlBupropion Hcl | 53 | $1,462 |
| Duloxetine Hcl | 89 | $1,301 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 24 | $1,192 |
| Buspirone Hcl | 73 | $1,042 |
| Trazodone Hcl | 82 | $1,023 |
| Gabapentin | 67 | $971 |
| Famotidine | 17 | $848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $45 | $24,11233 claims |
| Lilly USA, LLCOlanzapine | $42 | $2,23381 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 154 adult health providers in Arkansas.
Other adult health in Springdale
- Amber AndersonSpringdale$2K
- Holly MooreLittle Rock$59K
- Deborah ShipmanJonesboro$41K
- Lisa HurdJonesboro$12K
- Kari SchrankFayetteville$9K
- Amanda McClureFayetteville$9K
- Gina NullFort Smith$8K
- Darren CompasBentonville$8K
- Lisa HarveyHot Springs$8K
- Marie JonesFayetteville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.